November 03, 2020
Eight medicines received add-on reimbursement status in October in the Netherlands
In October 2020, the Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa) registered add-on status for eight medicines, including four agents for cancer treatment, two medicines for rheumatoid arthritis, one medicine for Crohn's disease treatment, and one age for treatment of fungal infections.

Add-on medicines fall under the category "Other healthcare products" of the DRG system. They are reimbursed separately in addition to the DRG tariff when provided as a part of specialist medical care. The tariffs for add-on medicines are defined by the Dutch Healthcare Authority (NZa) at the national level.

The following medicines received add-on status in October 2020:

  • Gemcitabine infusion solution concentrate 40mg / ml vial 25 ml with a tariff of €45.67 for 1 piece
  • Gemcitabine infusion solution concentrate 40mg / ml vial 50 ml with a tariff of €91.34 for 1 piece
  • Gemcitabine infusion solution concentrate 40mg / ml vial 5 ml with a tariff of €9.12 for 1 piece
  • Hyrimoz 20mg injection 50mg / ml in disposable syringe 0.4 ml with a tariff of €393.35 for 2 pieces
  • Imraldi 40 injection solution 50mg / ml pen 0.8 ml with a tariff of €708.01 for 2 pieces
  • Lomustine Eureco-Pharma capsule 40mg with a tariff of €802.79 for 20 pieces
  • Lorviqua film-coated tablet 100 mg with a tariff of €6,664.70 for 30 pieces
  • Lorviqua film-coated tablet 25 mg with a tariff of €6,664.70 for 90 pieces
  • Posaconazole Abdi tablet 100 mg with a tariff of €557.86 for 24 pieces
  • Posaconazole Mylan tablet 100 mg with a tariff of € 581.10 for 24 pieces
  • Xeljanz tablet film-coated 5mg with a tariff of €581.10 for 56 pieces
  • Ledaga gel 160 mcg / g 60g with a tariff of €1,635 for 1 piece

The full details in Dutch can be found here.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Close